Literature DB >> 25205195

Imidazo[1,2-a]pyridine-based peptidomimetics as inhibitors of Akt.

Young B Kim1, Chang Won Kang1, Sujeewa Ranatunga1, Hua Yang1, Said M Sebti1, Juan R Del Valle1.   

Abstract

We report the design, synthesis, and biological evaluation of imidazopyridine-based peptidomimetics based on the substrate consensus sequence of Akt, an AGC family serine/threonine kinase hyperactivated in over 50% of human tumors. Our ligand-based approach led to the identification of novel substrate mimetic inhibitors of Akt1 featuring an unnatural extended dipeptide surrogate. Compound 11 inhibits Akt isoforms in the sub-micromolar range and exhibits improved proteolytic stability relative to a parent pentapeptide.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Dipeptide surrogate; Kinase inhibitor; Peptide mimic; β-Strand mimic

Mesh:

Substances:

Year:  2014        PMID: 25205195      PMCID: PMC4176526          DOI: 10.1016/j.bmcl.2014.08.040

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  30 in total

Review 1.  Regulation of the Akt kinase by interacting proteins.

Authors:  Keyong Du; Philip N Tsichlis
Journal:  Oncogene       Date:  2005-11-14       Impact factor: 9.867

2.  Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors.

Authors:  Craig W Lindsley; Zhijian Zhao; William H Leister; Ronald G Robinson; Stanley F Barnett; Deborah Defeo-Jones; Raymond E Jones; George D Hartman; Joel R Huff; Hans E Huber; Mark E Duggan
Journal:  Bioorg Med Chem Lett       Date:  2005-02-01       Impact factor: 2.823

Review 3.  The Akt/PKB pathway: molecular target for cancer drug discovery.

Authors:  Jin Q Cheng; Craig W Lindsley; George Z Cheng; Hua Yang; Santo V Nicosia
Journal:  Oncogene       Date:  2005-11-14       Impact factor: 9.867

Review 4.  AKT crystal structure and AKT-specific inhibitors.

Authors:  Chandra C Kumar; Vincent Madison
Journal:  Oncogene       Date:  2005-11-14       Impact factor: 9.867

Review 5.  Perturbations of the AKT signaling pathway in human cancer.

Authors:  Deborah A Altomare; Joseph R Testa
Journal:  Oncogene       Date:  2005-11-14       Impact factor: 9.867

6.  Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma.

Authors:  S P Staal
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

Review 7.  The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation.

Authors:  Stanley F Barnett; Mark T Bilodeau; Craig W Lindsley
Journal:  Curr Top Med Chem       Date:  2005       Impact factor: 3.295

8.  Isolation of transforming murine leukemia viruses from mice with a high incidence of spontaneous lymphoma.

Authors:  S P Staal; J W Hartley; W P Rowe
Journal:  Proc Natl Acad Sci U S A       Date:  1977-07       Impact factor: 11.205

9.  AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas.

Authors:  J Q Cheng; A K Godwin; A Bellacosa; T Taguchi; T F Franke; T C Hamilton; P N Tsichlis; J R Testa
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

10.  Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas.

Authors:  A Bellacosa; D de Feo; A K Godwin; D W Bell; J Q Cheng; D A Altomare; M Wan; L Dubeau; G Scambia; V Masciullo; G Ferrandina; P Benedetti Panici; S Mancuso; G Neri; J R Testa
Journal:  Int J Cancer       Date:  1995-08-22       Impact factor: 7.396

View more
  2 in total

Review 1.  Targeting kinase signaling pathways with constrained peptide scaffolds.

Authors:  Laura E Hanold; Melody D Fulton; Eileen J Kennedy
Journal:  Pharmacol Ther       Date:  2017-02-07       Impact factor: 12.310

2.  SAR Probing of KX2-391 Provided Analogues With Juxtaposed Activity Profile Against Major Oncogenic Kinases.

Authors:  Abdelsattar M Omar; Maan T Khayat; Farid Ahmed; Yosra A Muhammad; Azizah M Malebari; Sara M Ibrahim; Mohammad I Khan; Dhaval K Shah; Wayne E Childers; Moustafa E El-Araby
Journal:  Front Oncol       Date:  2022-05-20       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.